Doxazosin Mesylate
30 NDCs across 7 manufacturers|29 Generic,1 Brand
Doxazosin Mesylate is used to treat hypertension, prostatic hyperplasia and urinary retention, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Nov 2, 1990, and the first generic was approved Oct 18, 2000. FDA's Orange Book lists 40 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $37 million on Doxazosin Mesylate across 2.2 million claims for 534,000 beneficiaries.
Doxazosin Mesylate is available as 30 NDCs from 7 manufacturers (29 generic, 1 brand), with NADAC prices from $0.06 to $6.99 per EA — the most expensive product costs about 110× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
30
29G / 1B
Manufacturers
7
competing in market
Price Spread
$0.06 – $6.99
per EA
7d Activity
avg -2.6% WoW · of 30 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Unichem Pharmaceuticals (USA) Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
alpha-Adrenergic Blocker class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
7 manufacturers producing DOXAZOSIN MESYLATE(1 pricing outlier)
Frequently Asked Questions
What is Doxazosin Mesylate used to treat?
Doxazosin Mesylate is used to treat hypertension, prostatic hyperplasia and urinary retention, per the National Library of Medicine's MED-RT classification.
When did Doxazosin Mesylate become available as a generic?
FDA approved the first generic Doxazosin Mesylate (ANDA) on Oct 18, 2000. The Orange Book currently lists 40 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Doxazosin Mesylate?
In 2024, Medicare Part D spent $37 million on Doxazosin Mesylate across 2.2 million claims for 534,000 beneficiaries.
How many Doxazosin Mesylate products are on the market?
The Doxazosin Mesylate drug market contains 30 NDCs from 7 manufacturers — 29 generic and 1 brand product.
What is the price range for Doxazosin Mesylate?
NADAC reference prices for Doxazosin Mesylate range from $0.0635 to $6.9889 per EA — the most expensive product costs about 110× the cheapest.
Is generic Doxazosin Mesylate cheaper than brand?
The average generic NADAC for Doxazosin Mesylate is $0.0798 per EA, versus $6.9889 for brand-labeled products — brand versions average about 88× the generic price.
Which manufacturers make Doxazosin Mesylate?
7 manufacturers list Doxazosin Mesylate in NADAC. Ranked by number of NDCs, the largest are Unichem Pharmaceuticals (USA) Inc. (8), Aurobindo Pharma Limited (7), Chartwell RX LLC (4), Upsher-Smith Laboratories LLC (4), Teva Pharmaceuticals USA Inc. (4).
How has the price of Doxazosin Mesylate changed recently?
Over the past 7 days, 0 Doxazosin Mesylate NDCs rose and 30 fell, with a market-wide average change of -2.6%.